Innovation & Achievement

Recent Announcements

PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial

PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial

PhotoPharmics, a clinical-stage medical device company pioneering Photo Neuromodulation for neurodegenerative disease, today announced it has surpassed its enrollment target with 350 participants in its pivotal, Phase 3 Light for PD clinical trial evaluating the Celeste® device for people living with Parkinson’s disease.

“Exceeding our target and closing enrollment is a remarkable milestone for the Parkinson’s community,” said Kent Savage, Chief Executive Officer of PhotoPharmics. “We’re proving that rigorous science can be both patient-centered and home-based. We’re deeply grateful to our investigators, study teams, and especially our participants and their families, whose courage and commitment make this work possible.”

read more

Featured Article

Young-Onset Parkinson’s: Navigating Your Journey After an Early Diagnosis

An early diagnosis of Young-Onset Parkinson’s Disease (YOPD) presents a unique set of challenges during the prime of your life. This blog serves as a proactive roadmap for navigating your journey, exploring the differences in YOPD symptoms, modern treatment strategies, the critical role of exercise and mental health, and how to manage your career and family life with confidence.

Archived Content

Social Media

[custom-twitter-feeds]

Facebook

[custom-facebook-feed]

Instagram

[instagram-feed num=4 cols=4 showfollow=false showbutton=false]